Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


Featured Session: Diagnosis & Management of Rare Disease

We are at a major inflection point in our ability to use clinical genomic information to diagnosis and manage thousands of rare diseases, yet the ability to ensure patient access to this information and innovative science remains unrealized due to an array of complex barriers. With 30 million patients in the U.S. and 300 million around the globe living with the burden of a rare disease, this unmet medical need is substantial. The panel includes a variety of stakeholders involved in finding innovative solutions to remove these barriers for patients and their healthcare providers in today’s fragmented medical care system.


Patrice Milos, PH.D., President and CEO, Claritas Genomics

Dr. Milos, a pioneer at the interface of genomics and medicine, leads Claritas in its mission to serve children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers, combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, to improve pediatric precision care. Read Full Bio

Sharon Terry, President and CEO, Genetic Alliance

Sharon Terry is President and CEO of the Genetic Alliance, a network transforming health by promoting openness and is founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). Read Full Bio

Timothy Yu, M.D., Ph.D., Boston Children's Hospital

Dr. Yu is a practicing neurologist and researcher at Boston Children’s Hospital with broad expertise in genomics, informatics, and pediatric precision care. His research focuses on developing and applying high throughput sequencing methods to identify novel disease genes for intellectual disability and autism. Read Full Bio

Albert Seymour, Ph.D, Head of Research and Non-clinical Development, Shire Pharmaceuticals

Albert is a human geneticist with more than 17 years of scientific and leadership experience in drug discovery and development. Albert joined Shire in April of 2011 and currently he is the Head of Research and Nonclinical Development (RNCD) at Shire. Read Full Bio

Web Analytics